৳ 200/unit
Pack: ৳ 2,000
৳ 200/unit
Pack: ৳ 2,000
At a glance
Dasatinib is a tyrosine kinase inhibitor (TKI) used for the treatment of chronic myeloid leukemia (CML) and acute lymphoblastic leukemia (ALL).
Indications
- Chronic Myeloid Leukemia (CML)
- Acute Lymphoblastic Leukemia (ALL)
Pharmacology
Dasatinib is a tyrosine kinase inhibitor that inhibits multiple kinases including BCR-ABL, SRC family, c-KIT, PDGFR-β, and EPHA2. It is effective in imatinib-resistant CML patients.
Dosage
Adult - CML (Chronic Phase): 100 mg once daily orally.
Adult - CML (Accelerated or Blast Phase): 140 mg once daily orally.
Adult - ALL: 140 mg once daily orally.
May be taken with or without food.
Side effects
Common: Diarrhea, headache, fatigue, nausea, rash, muscle pain, pleural effusion, edema, neutropenia, thrombocytopenia, anemia.
Serious: Myelosuppression, bleeding, fluid retention (pleural effusion, pericardial effusion), QT prolongation, pulmonary hypertension.
Use in pregnancy
Pregnancy Category D. Dasatinib is unsafe during pregnancy as there is definite evidence of risk to the developing baby. May be used in life-threatening situations if benefits outweigh risks.
Pregnancy Category: D — always consult a doctor before taking during pregnancy.
Precautions & warnings
Myelosuppression: Monitor blood counts regularly; Fluid retention: Monitor weight and dyspnea; Bleeding risk; QT prolongation: ECG monitoring; Avoid pregnancy; Monitor liver function tests.
Overdose effects
Overdose may lead to myelosuppression, nausea, diarrhea, and other side effects. Seek medical attention.
Storage conditions
Store below 30°C in a dry place. Keep out of reach of children.